2007: Epidemiology and Health Services Research III
Search or Browse by Day

Epidemiology and Health Services Research III

Saturday, November 10, 2007
1484
Individualizing the Measure of Functional Impairment in Rheumatoid Arthritis (RA): Development of Patient-Specific Forms of the Health Assessment Questionnaire (HAQ)
1485
An OARSI/OMERACT Initiative: The Development of Short Measures of Physical Function for Knee and Hip OA KOOS-Physical Function Shortform (KOOS-PS) and HOOS-Physical Function Shortform (HOOS-PS)
1486
Improved Precision of a Lower Extremity Osteoarthritis Functional Outcome Instrument
1487
What Diseases Do Rheumatologists Treat? Analysis of a Large Community Based Practice
1488
Osteoarthritis or Rheumatoid Arthritis - Are Individuals Concerned in the General Population Able to Differentiate? Results from the German Rheumatoid Arthritis Population Survey (GRAPS)
1489
Effect of Abatacept Treatment on Patient Activity Participation in Rheumatoid Arthritis
1490
Effect of Lupus on Sexual Health of Women
1491
Psychosocial Factors are Associated with Poor Mental and Physical Health-Related Quality of Life in Subjects with New Onset Chronic Widespread Pain
1492
The Impact of Demographic and Psychosocial Characteristics on Health-Related Quality of Life in Patients with Early Inflammatory Joint Complaints
1493
Prediction Models for Disease: The Effect of Associations between Markers on Calculating the Risk for Disease by Likelihood Ratio Products
1494
Ankylosing Spondylitis (AS) Patients on Adalimumab Show Sustained Improvement in Health-Related Quality of Life (HRQOL): 104-Week Results from ATLAS
1495
What Matters to People in Spondyloarthritis (SpA): Measuring the Importance of Valued Life Activities
1496
Investigating What Aspects of Sleep Improve in Rheumatoid Arthritis Patients Treated with Abatacept
1497
Validation of the DAS28 Definition Based on CRP Compared with DAS28 Based on ESR Using Data from Patients with Rheumatoid Arthritis Treated with Abatacept
1498
Abnormal Psychological Attachment is Associated with the Onset of Chronic Widespread Pain
1499
Understanding the Pain Experience in Hip and Knee OA
1500
Common Sleep Habits of Older Community-Living People with Osteoarthritis
1501
Efficacy of Etoricoxib in the Treatment of Osteoarthritis as Compared to Acetaminophen, Traditional NSAIDs and Cox-2 selective NSAIDs: A Bayesian Meta-analysis of Direct and Indirect Comparisons
1502
How Useful is the “Help from Others, Aids & Devices” in Scoring the Health Assessment Questionnaire (HAQ)?
1503
Predictors of Frequent Emergency Department Use among Persons with Systemic Lupus Erythematosus
1504
Health Status in Inflammatory Arthritis Patients with "Worse Than Death" EQ-5D Scores
1505
Ambulatory Medical Care Visits by Adults for Arthritis and Other Rheumatic Conditions (aorc) are Increasing, United States, 2002-2004 Vs. 1997
1506
Chronic Musculoskeletal Pain Predicts an Increased Risk for Hospital Care
1507
Description of Lifetime Physical Activity by Time, Energy and Joint Force in a Canadian Sample
1508
Investigation of Response Shift in Health Related Quality of Life scores Among Patients Undergoing Total Knee Replacement
1509
The Development of a Rheumatic Disease Research Comorbidity Index for Use in Outpatients with RA, OA, SLE and Fibromyalgia (FMS)
1510
Valuation Of Health States for Scleroderma and Psoriatic Arthritis by the General Public: Community Weights for Future Decision and Cost-effectiveness Analyses
1511
Respective Value of a Specific and of a Generic Questionnaire in the Measurement of Quality of Life in Osteoarthritis: Insights from Item Response Theory Modelling
1512
Baseline Disease Activity Determines the Level of Improvement Needed to Experience a Minimal and Major Response in Rheumatoid Arthritis
1513
Most TNF Inhibitor Trials in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) are Undeservedly Called “Efficacy And Safety” Trials: Type II Error in Reporting Safety Data
1514
Household Income and Quality of Life in Patients with Rheumatoid Arthritis: Results from a Mestizo Population with Full Health-Care Coverage
1515
The Cutoff Points of Antinuclear Antibody with High Negative and Positive Predictive Values. Analysis of 5655 Cases
1516
Improving the Health Assessment Questionaire: The HAQ-100
1517
NSAIDs in the Management of Musculoskeletal Conditions: A Comparative Meta-Analysis of the Efficacy/Safety Profile of Piroxicam
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>